Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

Clinical Infectious Diseases

Volumn 41, Issue 10, 2005, Pages 1407-1415

  Jauregui, Luis E ^a   Babazadeh, Simon ^b   Seltzer, Elyse ^e   Goldberg, Lisa ^e   Krievins, Dainis ^g   Frederick, Mark ^c   Krause, David ^e   Satilovs, Igors ^h   Endzinas, Zilvinas ⁱ   Breaux, Jeffrey ^f   O'Riordan, William ^d  

^a ST VINCENT MERCY MEDICAL CENTER   (United States)

^b Crest Clinical Trials   (United States)

^c Talbert Medical Group   (United States)

^d eStudy Site   (United States)

^e Vicuron Pharmaceuticals   (United States)

^f Gulf Coast Research Associates   (United States)

^g PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^h Daugavpils Regional Hospital   (Latvia)

ⁱ KAUNAS UNIVERSITY OF MEDICINE HOSPITAL   (Lithuania)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AZTREONAM; DALBAVANCIN; GAMMA GLUTAMYLTRANSFERASE; GLYCOPEPTIDE; LACTATE DEHYDROGENASE; LINEZOLID; METRONIDAZOLE; PLACEBO;

ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BURN; BURN INFECTION; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; MYCOSIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SKIN ABSCESS; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS GROUP C; STREPTOCOCCUS GROUP G; STREPTOCOCCUS PYOGENES; SURGICAL INFECTION; THROMBOCYTOPENIA; VOMITING;

ACETAMIDES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; SKIN DISEASES, BACTERIAL; TEICOPLANIN; TIME FACTORS;

EID: 27644549908     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/497271     Document Type: Article

References (25)

1. Lin G, Credito K, Ednie LM, Appelbaum PC. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005; 49:770-2.
2. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004; 48:137-43.
3. Candiani G, Abbondi M, Borgonovi M, Romano G, Parenti F. In vitro and in vivo antibacterial activity of B1 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999; 44:179-92.
4. Lefort A, Pavie J, Garry L, Chau F, Fantin B. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob Agents Chemother 2004; 48:1061-4.
5. Jabes D, Candiani G, Romano G, Brunati C, Riva S, Cavaleri M. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother 2004; 48:1118-23.
6. Kontianien S, Rinne E. Bacteria isolated from skin and soft tissue lesions. Eur J Clin Microbiol 1985; 6:420-2.
7. Centers for Disease Control and Prevention National Nosocomial Infections Surveillance (NNIS) System. NNIS system report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31:481-98.
8. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. The Dalbavancin Skin and Soft-Tissue Infection Study Group. Clin Infect Dis 2003; 37:1298-303.
9. Hwang IK, Morikawa T. Design issues in noninferiority/equivalence trials. Drug Inf J 1999; 33:1205-18.
10. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44:3408-13.
11. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001; 61:525-51.
12. Arbeit RD, Maki D, Tally F, Campanaro E, Eisenstein B. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. The Daptomycin 98-01 and 99-01 Investigators. Clin Infect Dis 2004; 38:1673-81.
13. Gesser RM, McCarroll KA, Woods GL. Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam. Int J Antimicrob Agents 2004; 23:235-9.
14. Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002; 34:1460-8.
15. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother 1999; 44:263-73.
16. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7:178-82.
17. Barrett TW, Moran GJ. Update on emerging infections: news from the Centers for Disease Control and Prevention [commentary]. Ann Emerg Med 2004; 43:45-47.
18. Cohen PR, Kurzrock R. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem. J Am Acad Dermatol 2004; 50:277-80.
19. Gorak EJ, Yamada SM, Brown JD. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999; 29:797-800.
20. Gosbell IB. Methicillin-resistant Staphylococcus aureus: impact on dermatology practice. Am J Clin Dermatol 2004; 5:239-59.
21. Zinderman CE, Conner B, Malakooti MA, LaMar JE, Armstrong A, Bohnker BK. Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerg Infect Dis 2004; 10:941-4.
22. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized open-label trial. Clin Infect Dis 2002; 35:381-9.
23. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt) 2003; 4:57-70.
24. Nathwani D. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? J Antimicrob Chemother 2003; 51(Suppl S2): ii37-44.
25. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36:592-8.